Search Results - "Molden, Nandini"

Anti-TIGIT antibody tiragolumab improves PD-L1 blockade via myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin, Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl, Duong, Ellen, Dunkle, Alexis, Chang, Patrick, Han, Joy, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi

“…Tiragolumab, an anti-TIGIT antibody with an active IgG1/kappa Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial when combined with atezolizumab…”
Get full text

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

“…Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 )…”
Get full text

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

Get full text

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

Get full text

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

Get full text

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y, Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L, Duong, Ellen, Dunkle, Alexis, Chang, Patrick S, Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S, Meng, Raymond, Chiang, Eugene Y, Johnston, Robert J, Patil, Namrata S

Get full text

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y, Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L, Duong, Ellen, Dunkle, Alexis, Chang, Patrick S, Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S, Meng, Raymond, Chiang, Eugene Y, Johnston, Robert J, Patil, Namrata S

Get full text

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y, Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L, Duong, Ellen, Dunkle, Alexis, Chang, Patrick S, Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S, Meng, Raymond, Chiang, Eugene Y, Johnston, Robert J, Patil, Namrata S

Get full text

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y, Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L, Duong, Ellen, Dunkle, Alexis, Chang, Patrick S, Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S, Meng, Raymond, Chiang, Eugene Y, Johnston, Robert J, Patil, Namrata S

“…Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 )…”
Get full text

Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade by Patil, Namrata S., Srivats, Shyam, Choi, Yoonha, Guan, Xiangnan, Nabet, Barzin, McGinnis, Lisa, Chiang, Eugene, Dunkle, Alexis, O’Gorman, Bill, Chang, Patrick S., Hu, Ruozhen, Silva, John, Han, Joy, Au-Yeung, Amelia, Takahashi, Chikara, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Meng, Raymond, Mariathasan, Sanjeev, Johnston, Robert, Shames, David S.

“…Background: TIGIT is a co-inhibitory receptor and immune checkpoint associated with T cell and natural killer (NK) cell dysfunction in cancer. Tiragolumab is…”
Get full text